

Leptin as Severity Index of Psoriasis and its Correlation to The Metabolic Syndrome

Thesis

Submitted For Partial Fulfillment of M.D Degree in Dermatology
and Venereology

By

Christine kamal Thabet Gobrial

M.Sc. Dermatology and Venereology

Ain Shams University

Under Supervision of

Prof. Dr. Naziha Hafez Khafagy

Professor of Dermatology and Venereology

Ain Shams University

Prof.Dr. Tarek Mahmoud El-Ghandour

Professor of Dermatology and Venereology

Ain Shams University

Prof.Dr. Eman Abdel-Monium Al-Gohary

Professor of Clinical and Chemical Pathology

Ain Shams University

Prof.Dr. Nafissa Amin El Badawy

Professor of Pathology

Ain Shams University

Faculty of Medicine

Ain Shams University

2012

Contents

Topic	page
Contents	i
List of figures	iii
List of tables	v
List of abbreviations	x
1. Introduction & Aim of work	1
2.0. Review of literature	5
2.1. A general view on psoriasis	5
Epidemiology of psoriasis	
Genetic aspects of psoriasis	
Precipitating factors of psoriasis	
Clinical picture of psoriasis	
Histopathology of Psoriasis	
Immunopathogenesis of Psoriasis	
2.2. Leptin as an Adipocytokine	34
Leptin	
Leptin structure	
Leptin receptor	
Leptin binding protein	

Leptin receptor binding model	
Leptin signal transduction	
Therapeutic application	
Conclusion	
2.3. Metabolic syndrome	60
Introduction	
Various factors contributing to increasing prevalence of metabolic syndrome	
Aetiopathogenesis	
Adipose tissue inflammation during obesity	
Adipokines, inflammation and insulin resistance	
Management of metabolic syndrome	
2.4. Leptin, metabolic syndrome & psoriasis	83
3. Subjects and methods	98
4. Results	113
5. Discussion	152
6. Conclusion & recommendations	165
7. Summary	168
8. References	175
9.0. Arabic summary	

List of figures

Fig. (1)	T-cell activation, proliferation and cytokine production (Krueger, 2002)
Fig. (2)	T cell binding and trafficking into the dermis and epidermis (Krueger, 2002)
Fig. (3)	The psoriatic cascade (Krueger, 2002)
Fig. (4)	Crystal structure of Leptin (Zhang et al., 1997)
Fig. (5)	Adipokine expression and secretion by adipose tissue in lean subjects (Bastard et al., 2006)
Fig. (6)	Adipokine expression and secretion by adipose tissue in insulin-resistant, obese subjects (Bastard et al., 2006)
Fig. (7)	Comparison of the mean plasma leptin concentrations between the patients and the controls
Fig. (8)	Comparison between the prevalence of tissue staining of leptin receptor in the controls and the patients of (G3) before treatment
Fig. (9)	Comparison of the mean plasma leptin concentration between the MS–ve and MS+ve controls
Fig. (10)	Comparison between mean changes (reduction) in PASI score in the patients of (G3) (after receiving different treatments)
Fig. (11)	Comparison between mean changes (reduction) in plasma leptin concentration in the patients of (G3) (after receiving different treatments)

Fig. (12)	Comparison between mean PASI scores in the patients of (G3) (before and after receiving different treatments)
Fig. (13)	Comparison between mean plasma leptin concentrations in the patients of (G3) (before and after receiving different treatments)
Fig. (14)	Comparison between mean tissue leptin receptor expressions in the patients of (G3) (before and after receiving different treatments)
Fig. (15)	Comparison between mean plasma leptin concentrations in the controls and different PASI score groups (N= 40 control, 30 mild-moderate (G1) and 30 severe (G2))
Fig. (16)	Comparison between mean plasma leptin concentrations in the mild-moderate and severe PASI groups of patients in (G3) (N = 30) (before and after treatment)
Fig. (17)	Comparison between the prevalence of tissue leptin receptor staining in the controls and the patients of (G3) with different severities (before treatment)
Fig. (18)	Comparison between the prevalence of nuclear leptin receptor staining in the patients of (G3) with different severities (before treatment)
Fig. (19)	Comparison between the prevalence of dermal staining in the patients of (G3) with different severities (before treatment)
Fig. (20-23)	Clinical pictures of some of our patients pre and after treatment
Fig. (24-32)	Histopathology pictures of some of our patients pre and after treatment

List of tables

Table(1)	Cytokines and chemokines that play a role in the immunologic cascade of psoriasis (<i>Mehlis and Gordon, 2004</i>).
Table(2)	Descriptive statistics and test of significance for the difference in age and clinical parameters between the patients and the controls
Table(3)	Descriptive statistics and test of significance for the difference in plasma measurements between the patients (before treatment) and the controls
Table(4)	Prevalence of metabolic syndrome in the patients and the controls
Table(5)	Prevalence of tissue leptin receptors staining in the controls and the patients of (G3) (before treatment)
Table(6)	Descriptive statistics and test of significance for the difference in plasma measurements between the male and female controls (N = 40)
Table(7)	Descriptive statistics and test of significance for the difference in age and clinical parameters between the female and male patients (N = 60)
Table(8)	Descriptive statistics and test of significance for the difference in plasma measurements between the female and male patients (before treatment) (N = 60)

Table(9)	Prevalence of metabolic syndrome in the female and male patients (N=60)
Table(10)	Prevalence of tissue leptin receptor staining in the female and male patients (G3) before treatment (N=30)
Table(11)	Descriptive statistics and test of significance for the difference in plasma measurements between MS–ve and MS+ve controls (N = 40)
Table(12)	Descriptive statistics and test of significance for the difference in age and clinical parameters between MS–ve and MS+ve patients (N = 60)
Table(13)	Descriptive statistics and test of significance for the difference in plasma measurements between MS–ve and MS+ve patients before treatment (N = 60)
Table(14)	Descriptive statistics and test of significance for the difference in plasma measurements between MS–ve and MS+ve patients of (G3) before treatment (N = 30)
Table(15)	Descriptive statistics and test of significance for the difference in plasma measurements between MS–ve and MS+ve patients of (G3) after receiving different treatments (N = 30)
Table(16)	Prevalence of metabolic syndrome in the patients of (G3) (before treatment) (N = 30)
Table(17)	Prevalence of tissue leptin receptor staining in the patients of (G3) (before treatment) (N = 30)

Table(18)	Prevalence of tissue leptin receptor staining in the patients of (G3) (after receiving different treatments) (N = 30)
Table(19)	Descriptive statistics and test of significance for the difference in plasma measurements between the patients of (G3) (before treatment) (N = 30)
Table(20)	Descriptive statistics and test of significance for the difference in plasma measurements between the patients of (G3) (after receiving different treatments) (N = 30)
Table(21)	Descriptive statistics and test of significance for the difference in changes in plasma measurements (after -before treatment) between the patients of (G3) (N = 30)
Table(22)	Descriptive statistics and test of significance for the effect of different treatments on plasma and tissue measurements in the patients of (G3) (N = 30)
Table(23)	Descriptive statistics and test of significance for the effect of treatment on plasma and tissue measurements in the patients using Topical treatment (N = 10)
Table(24)	Descriptive statistics and test of significance for the effect of treatment on plasma and tissue measurements in the patients using PUVA treatment (N = 10)
Table(25)	Descriptive statistics and test of significance for the effect of treatment on plasma and tissue measurements in the patients using methotrexate treatment (N = 10)

Table(26)	Descriptive statistics and test of significance for the effect of PASI score on age and clinical parameters of the patients (N= 30 mild-moderate (G1) & 30 severe (G2)) in comparison to the controls (N = 40)
Table(27)	Descriptive statistics and test of significance for the effect of PASI score on plasma measurements of the patients before treatment (N = 30 mild-moderate (G1) & 30 severe (G2)) in comparison to the controls (N = 40)
Table(28)	Descriptive statistics and test of significance for the difference in plasma measurements between the mild-moderate and severe patients in (G3) (N = 30) (before treatment)
Table(29)	Descriptive statistics and test of significance for the difference in plasma measurements between mild- moderate and severe patients in (G3) (N = 30) (after treatment)
Table(30)	Descriptive statistics and test of significance for the difference in changes in plasma measurements (after -before treatment) between the mild-moderate and severe patients in (G3) (N = 30)
Table(31)	Prevalence of metabolic syndrome in control and different PASI score groups (G1 and G2) (N=60)
Table(32)	Prevalence of tissue staining of leptin receptor in the controls and the patients of (G3) with different severities (N=30) (before treatment)
Table(33)	Prevalence of tissue staining of leptin receptors in the patients of (G3) with different severities (N=30)

Table(34)	Prevalence of nuclear leptin receptors staining in the patients of (G3) with different severities (N=30) (before treatment)
Table(35)	Prevalence of nuclear leptin receptors staining in patients of (G3) with different severities (after treatment)
Table(36)	Prevalence of dermal leptin receptors staining in the patients of (G3) with different severities (N=30)
Table(37)	Effect of the presence of the MS criteria on treatment outcome (according to changes in PASI score)

List of Abbreviations

A °	Angstrom
ACE	Angiotensin converting enzyme
ACRP30	Adipocyte complement-related protein of 30 kDa
AHA	American Heart Association
AMP	Adenosine mono phosphate
AMPK	AMP activated protein kinase
APC	Antigen presenting cells
APM1	Adipose most abundant gene transcript 1
ATP III	Adult Treatment Panel III
BBB	Blood–brain barrier
BMI	Body mass index
BP	Blood pressure
cAMP	Cyclic adenosine mono-phosphate
CD	Cluster of differentiation
CHD	Coronary heart disease
CLA	Cutaneous lymphocyte antigen
COX-2	Cyclooxygenase-2
CRP	C- reactive protein
CVD	Cardio-vascular diseases
DASH	Dietary approaches to Stop Hypertension
DB	Diabetes
DC	Dendritic cells
iDC	immature dendritic cell
mDC	mature DCs
pDC	plasmacytoid dendritic cells
DNA	Deoxyribonucleic acid
EGF-R	Epidermal growth factor receptor
ELISA	Enzyme linked immunosorbent assay
EPO	Erythropoietin
FA	Fatty acid
FIZZ3	Found in inflammatory zones
GBP28	Gelatin-binding protein 28

GH	Growth hormone
Glu	Glutamine
GM-CSF	Granulocyte-monocyte colony stimulating factor
gp	Glyco-protein
HDL	High density lipoprotein
HIV	Human immune deficiency virus
HLA	Human leukocyte antigen
ICAM-1	Intercellular adhesion molecule-1
Ig	Immunoglobulin
IL	Interleukin
IFN- α	Interferon alpha
IFN- γ	Interferon gamma
iNOS	Inducible nitric oxide synthase
IP-10	INF- γ inducible protein 10
IRAK	IL-1R-associated kinase
IRS	Insulin receptor substrate
JAK	Janus Kinases
Kcal	Kilo calory
KC	keratinocytes
KD	Kilo Dalton
LC	Langerhans cells
LDL	Low density lipoprotein
Lepr	Leptin receptor
LFA	Leukocyte function associated antigen
LIF	Leukemia inhibitory factor
LR	Leptin receptor
M	Monocyte
MAPK	Mitogen activated protein kinase
MCP-1	Monocyte chemoattractant protein- 1
MHC	Major Histocompatibility Complex
MIG	Monokine induced by INF- γ
MIP	Macrophage inflammatory protein
MS	Metabolic syndrome

m RNA	Messenger Ribonucleic acid
NHANES	National Health and Nutrition Examination Survey
NK	Natural killer
NPY	Neuropeptide Y
OB	Obese
PAI-1	Plasminogen activator inhibitor-1
PASI	Psoriasis area and severity index
PGE2	Prostaglandin E2
PI3K	Phosphatidylinositol 3 kinase
POMC	Pro-opiomelanocortin
PUVA	Psoralen plus ultra-violet A rays
RA	Rheumatoid arthritis
RANTES	Regulated upon activation, normal T cells expressed and secreted
SAT	Subcutaneous adipose tissue
SCID	Severe combined immunodeficiency
SD	Standard deviation
SH	Disulphahydryl groups
SLR	Soluble leptin receptor
SOCS3	Suppressor of cytokine signaling
STAT	Signal Transducers activators of Transcription
T-AP	Tcells- antigen presenting
TARC	Thymus and activation regulated chemokine
Tc	T cytotoxic
TCR	T cell rceptor
TGs	Triglycerides
TGF- α	Transforming growth factor α
TGF- β	Transforming growth factor β
Th	T helper
TNF- α	Tumour necrosis factor
TRH	Thyrotropin releasing hormone
Trp	Tryptophan
Tyr	Tyrosine
T2D	Type 2 diabetes

UVB	Ultraviolet B
UVA	Ultraviolet A
VAT	Visceral adipose tissue
VCAM-1	Vascular cell adhesion molecule-1
VEGF	Vascular endothelial growth factor
VLA-4	Very late antigen 4
VLDL	Very low density lipoprotein
WAT	White adipose tissue

Acknowledgments

Thanks to God first and foremost. I feel always indebted to God, the most kind and the most merciful.

*I would like to express my gratefulness and respect to **Prof. Dr. Naziha Hafez Khafagy** , Professor of Dermatology and Venereology, Ain Shams University, for her constructive and instructive comments and valuable suggestions. She encouraged me all the time for a better performance. Without her generous help, this work would not have been accomplished in its present picture.*

*I would like to express my deepest appreciation to **Prof. Dr. Tarek Mahmoud El-Ghandour** , Professor of Dermatology and Venereology, Ain Shams University, for his persistent help and encouraging support all over the time of working under his guidance.*

*I would like to express my real gratitude and appreciation to **Prof. Dr. Eman Abdel-Monium Al-Gohary**, Professor of Clinical and Chemical Pathology, Ain Shams University, for her sincere scientific efforts and moral help.*

*Special thanks and deepest gratefulness to **Prof. Dr. Nafissa Amin El Badawy**, Professor of Pathology, Ain Shams University, for her meticulous comments and scientific support and for giving me the honor of working under her supervision and valuable guidance.*